Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.

[1]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[2]  Kaanan P. Shah,et al.  Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.

[3]  Jerome Jourquin,et al.  Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes , 2019, JCO precision oncology.

[4]  J. Snowdon,et al.  Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists , 2019, Cancer medicine.

[5]  L. Saal,et al.  Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series , 2019, Scientific Reports.

[6]  M. Dell'aquila,et al.  Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort , 2019, Modern Pathology.

[7]  V. Prasad,et al.  Real-world Evidence-What Does It Really Mean? , 2019, JAMA oncology.

[8]  K. White,et al.  Transcriptome-based cancer type prediction for tumors of unknown origin. , 2019, Journal of Clinical Oncology.

[9]  F. Vecchio,et al.  ER−/PR+/HER2− breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases , 2019, The breast journal.

[10]  Steven J. M. Jones,et al.  Application of a Neural Network Whole Transcriptome–Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers , 2019, JAMA network open.

[11]  Kaanan P. Shah,et al.  Clinical validation of the tempus xT next-generation targeted oncology sequencing assay , 2019, Oncotarget.

[12]  L. O’Driscoll,et al.  2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype , 2019, Scientific Reports.

[13]  A. Giobbie-Hurder,et al.  Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.

[14]  S. Loi,et al.  Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies , 2019, Poster Session Abstracts.

[15]  D. Mitra,et al.  Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. , 2019, Breast.

[16]  J. Mardekian,et al.  Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study , 2019, Advances in Therapy.

[17]  S. Khozin,et al.  Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer , 2019, bioRxiv.

[18]  N. Ayoub,et al.  Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches , 2019, Breast cancer.

[19]  Rebecca A Miksad,et al.  Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. , 2018, The oncologist.

[20]  S. Robertson,et al.  Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant , 2019, Breast Cancer Research and Treatment.

[21]  V. Prasad,et al.  Improving observational studies in the era of big data , 2018, The Lancet.

[22]  E. Skovlund,et al.  The use of real-world data in cancer drug development. , 2018, European journal of cancer.

[23]  K. Abrams,et al.  The inclusion of real world evidence in clinical development planning , 2018, Trials.

[24]  J. Cortés,et al.  Is there a role for immunotherapy in HER2-positive breast cancer? , 2018, npj Breast Cancer.

[25]  Jun Zhang,et al.  Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer , 2018, Oncology letters.

[26]  Raymond M. Moore,et al.  Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing , 2018, Journal of the National Cancer Institute.

[27]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Geraghty,et al.  Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project , 2018, British Journal of Cancer.

[29]  Christine Y. Lu,et al.  Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016) , 2018, Breast Cancer Research and Treatment.

[30]  Kaanan P. Shah,et al.  Clinical validation of the Tempus xO assay , 2018, Oncotarget.

[31]  D. Bedognetti,et al.  NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..

[32]  L. Pusztai,et al.  An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes , 2018, British Journal of Cancer.

[33]  Christian Brueffer,et al.  Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative , 2018, JCO precision oncology.

[34]  Amy P. Abernethy,et al.  Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality , 2017, Clinical pharmacology and therapeutics.

[35]  M. Hajjari,et al.  HOTAIR: A Promising Long Non-coding RNA with Potential Role in Breast Invasive Carcinoma , 2017, Front. Genet..

[36]  S. Khozin,et al.  Real-world Data for Clinical Evidence Generation in Oncology. , 2017, Journal of the National Cancer Institute.

[37]  B. Gyawali,et al.  Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. , 2017, JCO precision oncology.

[38]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[39]  Daniel Fabbri,et al.  Analysis of Adjuvant Endocrine Therapy in Practice From Electronic Health Record Data of Patients With Breast Cancer. , 2017, JCO clinical cancer informatics.

[40]  S. Hare,et al.  mTOR function and therapeutic targeting in breast cancer. , 2017, American journal of cancer research.

[41]  Gretchen L. Gierach,et al.  Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting , 2017, JAMA oncology.

[42]  Nahed A. Soliman,et al.  Ki-67 as a prognostic marker according to breast cancer molecular subtype , 2016, Cancer biology & medicine.

[43]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[44]  M. Levy,et al.  Integrating cancer genomic data into electronic health records , 2016, Genome Medicine.

[45]  P. Park,et al.  A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.

[46]  Angela Cox,et al.  Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment , 2016, PloS one.

[47]  Fleur Fritz,et al.  Electronic health records to facilitate clinical research , 2016, Clinical Research in Cardiology.

[48]  Melissa A. Troester,et al.  Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification , 2016, Breast Cancer Research.

[49]  Liucun Zhu,et al.  Transcriptome sequencing uncovers a three–long noncoding RNA signature in predicting breast cancer survival , 2016, Scientific Reports.

[50]  Meinhard Kieser,et al.  A method for using real world data in breast cancer modeling , 2016, J. Biomed. Informatics.

[51]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[52]  Russell L. Rothman,et al.  The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm , 2015, Annals of Internal Medicine.

[53]  M. Bøgsted,et al.  Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Pazdur,et al.  FDA Approval: Blinatumomab , 2015, Clinical Cancer Research.

[55]  Ping Sun,et al.  Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. , 2015, JAMA.

[56]  A. Soltanian,et al.  A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer , 2015, Breast Cancer.

[57]  C. Sotiriou,et al.  Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology , 2014, BMC Genomics.

[58]  A. Abernethy,et al.  "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. , 2013, Clinical genitourinary cancer.

[59]  M. J. van de Vijver,et al.  Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  E. Perez,et al.  Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. , 2013 .

[61]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[62]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[63]  H. Nisenbaum,et al.  HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ , 2012, Cancer.

[64]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[65]  Liliana Florea,et al.  Transcriptomic landscape of breast cancers through mRNA sequencing , 2012, Scientific Reports.

[66]  H. Sinn,et al.  Triple-Negative Breast Cancer: Clinical and Histological Correlations , 2011, Breast Care.

[67]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Emmert-Buck,et al.  Current molecular diagnostics of breast cancer and the potential incorporation of microRNA , 2009, Expert review of molecular diagnostics.

[69]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.